- Plan to initiate a Pivotal Phase 2b trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the second half of 20221 with initial results from open-label period 1 expected in the first half of 2024
- Plan to initiate a Phase 2 trial in Graves’ Disease in early 2023 with initial results expected in the second half of 2023
- Immunovant expects a robust cadence of data every half year beginning in the second half of 2023 through the first half of 2025, including multiple clinical readouts in CIDP, Graves’ Disease, Myasthenia Gravis (MG), and Thyroid Eye Disease (TED)
- Company management will host an investor webcast today at 8 AM ET that can be accessed here.
Ozempic’s Surging Demand Has Novo Nordisk Restricting It in Europe, Plus An Older Generation Diabetes Drug: What’s Next?
Novo Nordisk A/S (NYSE: NVO) plans to limit starter kit supplies of Ozempic (semaglutide) in Europe and reduce the distribution of Victoza (liraglutide), aiming to bolster Ozempic's production, which has experienced a
